The company's share price decline mirrors its poor fundamental performance. The recent loss isn't as severe as the 13% annual loss investors endured over the past five years. Key metrics need improvement to generate enthusiasm.
$プレシジェン(PGEN.US)$Moomoo 24/7· 3 mins ago Precigen Receives Orphan Drug Designation For PRGN-2012 For Treatment Of Recurrent Respiratory Papillomatosis From The European Commission
Precigen's declining revenue may necessitate additional funding, potentially diluting existing shareholder stakes. Despite a decrease in cash burn, falling revenue raises apprehension. Investors are urged to fully comprehend business risks prior to investing.
$プレシジェン(PGEN.US)$will be releasing their earnings report on Monday. Just like in the past, they're well in tune with beating the projected -0.1 EPS estimate. If you aren't already loaded up, now is the time. If you dont already know, last quarter, the company beat EPS by $0.10, which was followed by a 21.09% increase in the share price the next day.
プレシジェンに関するコメント
News
Precigen Receives Orphan Drug Designation For PRGN-2012 For Treatment Of Recurrent Respiratory Papillomatosis From The European Commission
Coming in hot
TOP WATCH AH + 1/26 WATCHLIST ⚡️
$アドバンスト・マイクロ・デバイス(AMD)(AMD.US)$$アリディス・ファーマシューティカルズ(ARDS.US)$$アララム・テクノロジーズ(ALAR.US)$$180ライフ・サイエンス(ATNF.US)$$ファースト・ウェーブ・バイオファーマ(FWBI.US)$$IBM(IBM.US)$$マスターカード(MA.US)$$マイクロソフト(MSFT.US)$$ミューレン・オートモーティブ(MULN.US)$$ノボ・インテグレーテッド・サイエンシズ(NVOS.US)$$オキュファイア・ファーマ(OCUP.US)$$プレシジェン(PGEN.US)$$テスラ(TSLA.US)$$ミネルバ・サージカル(UTRS.US)$
コラムToday's Pre-Market Stock Movers: ACN, CRM, LEN, NVAX and More
In reaction to earnings/guidance:
• $ドイツ銀行(DB.US)$ +5.6%,$セールスフォース(CRM.US)$ +2.3%,$H.B.フラー(FUL.US)$ +2.2%,$トリップ・ドット・コム・グループ(TCOM.US)$ +0.7%
Other news:
• $プレシジェン(PGEN.US)$ +3.9% (names new COO)
• $スコーピオ・タンカーズ(STNG.US)$ +2.7% (reports it purchased its common shares in the open market and exercised a purchase option for an LR2 product tanker that is currently leased)
• $マリナス・ファーマシューティカルズ(MRNS.US)$ +1.6% (...
まだコメントはありません